At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 62 enrolled
Drug / intervention
Abatacept combination product (ACP)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Sub-study-A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate
In Brief
A Phase 3 clinical trial evaluating Abatacept combination product (ACP) for Rheumatoid Arthritis (RA). Completed, enrolled 62 participants.
Detailed Summary
The purpose of this study is to determine the safety and acceptability of a device used in place of traditional syringes for abatacept self-injection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis (RA)
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2009
Primary CompletionFeb 2010
Study CompletionJul 2010
First PostedJul 2010
TodayJul 2026
First PostedJul 30, 2010
Enrollment StartNov 1, 2009
Primary CompletionFeb 1, 2010
Study CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 15.9 years ago
Interventions
Abatacept combination product (ACP)device
Abatacept Solution, Subcutaneous, 125 mg/device, Weekly, 3 months